Teva Pharmaceutical Industries Ltd. (TEVA) is not shipping a generic, injectable version of the Sanofi-Aventis SA (SNY) colon-cancer drug Eloxatin due to a legal issue, a Teva spokeswoman confirmed on Monday.

Teva announced only last Tuesday that the U.S. Food and Drug Administration had authorized the Israeli company to make and launch injections of the drug, known generically as oxaliplatin. Hospira Inc. (HSP) announced FDA approval at the same time but followed up three days later by saying its approval for oxaliplatin products was suspended due to legal proceedings initiated by Sanofi against the FDA.

Teva has also been affected, spokeswoman Denise Bradley confirmed.

"Teva is not shipping further product until the legal issue is resolved," she said in an email. "We are hopeful to have a decision in the near future."

The drug at issue is used to treat patients with stage III colon cancer and advanced colorectal cancer.

Teva shares recently traded down 0.9% to $50.94.

-By Jon Kamp, Dow Jones Newswires; 617-654-6728; jon.kamp@dowjones.com